Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 381-400 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 381 | Star Catcher Industries, Inc. lowweak | Opp 1 Risk 2 | Thesis: There is insufficient reviewed evidence in these reviewed sources to support an opportunity thesis beyond a broad statement that the company is building space infrastructure. Why now: Why now is weak because the reviewed sources' membership rationale references article describing an orbital power grid concept, but no article or reviewed evidence are provided for ranking use. Caveats: No article is available for article. Coverage debug shows zero evidence after recent evidence window. Cannot elevate concept relevance into thesis attractiveness without direct business evidence. |
| 382 | Star Catcher Industries, Inc. lowweak | Opp 1 Risk 1 | Thesis: Reviewed evidence-level rationale suggests Star Catcher is a space startup building space-based power infrastructure, but the ranking reviewed sources provide no direct positive evidence retained inside the 90-day recent evidence window, so there is insufficient basis for a positive 1 year+ opportunity thesis from admissible evidence. Why now: Why now is weak because the company had 10 articles considered, but zero article IDs and zero evidence remained after the 90-day recent evidence window cutoff of March 29, 2026; recency-based business-state judgment is therefore unavailable from these reviewed sources. Caveats: No retained evidence after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Phase-2 membership rationale is not directional proof and cites support article IDs without, so it cannot be used as a fully cited factual thesis. |
| 383 | Starfighters Space lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources rationale suggests Starfighters Space has air-launch and hypersonic testing relevance, but no within the recent evidence window direct evidence or citable are present in the reviewed sources output, so that does not support a scored positive thesis here. Why now: There is no available within the recent evidence window evidence row after the March 29, 2026 cutoff; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for Starfighters Space. Caveats: Phase-2 membership rationale references multiple article IDs, but the reviewed sources provide no article for citation. |
| 384 | Starfish Space lowweak | Opp 1 Risk 1 | Thesis: Membership rationale indicates autonomous proximity-operations progress, but no retained 90-day direct positive evidence is available in the served reviewed sources to support a durable upside thesis. Why now: No retained article IDs or evidence remain after recent evidence filtering, so there is no current evidence-based catalyst in the reviewed sources. Caveats: Single-article historical context is not retained within the recent evidence window. Absence of negative evidence is not positive evidence. Scoring is conservative because the current reviewed sources is effectively ungrounded for direction. |
| 385 | Starlab lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supportable because the reviewed sources retains no direct positive evidence within the recent evidence window. Why now: Why now is weak: the reviewed sources indicates zero evidence after recent evidence window, so there is no retained current catalyst or current operating-state evidence for Starlab. Caveats: Coverage after recent evidence window is empty for this company. Phase-2 membership rationale references, but no article summary or quoted evidence is included in the retained reviewed sources, so it cannot be used for factual claims here. |
| 386 | StatSat lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources does not retain sufficient company-specific positive evidence to support an opportunity thesis. Why now: The membership rationale references article and says AISSat-4 is operated by StatSat, but no retained evidence or are present after recent evidence window, leaving recency and business impact uncertain. Caveats: The only described support is a limited operational reference, not a clear catalyst. No direct dated evidence row is retained in the reviewed sources. |
| 387 | Swedish Space Corporation lowweak | Opp 1 Risk 1 | Thesis: No supported positive thesis from the retained recent evidence window evidence. The reviewed sources only notes an indirect mention of international partnerships involving Sweden in a Firefly earnings transcript summary, without clearly establishing Swedish Space Corporation's role or business impact (: no provided in reviewed sources). Why now: There is no current catalyst supported by retained evidence. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window, so recency and business-state changes cannot be assessed from these reviewed sources. Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Phase2 rationale is weaker than direct company-specific event evidence and should not be treated as strong proof. |
| 388 | Swoop Technologies lowweak | Opp 1 Risk 1 | Thesis: The only reviewed sources support is review-status context that Swoop was placed among Golden Dome contract awardees for networking/simulation, which could indicate defense/space-adjacent participation, but there is no direct positive evidence row or in the reviewed sources to support a durable opportunity thesis (: not provided in reviewed sources). Why now: No inside-recent evidence window evidence are available, and the reviewed sources reports articles after recent evidence window = 0 and evidence after recent evidence window = 0, so there is no supported near-term or long-horizon timing catalyst beyond generic context. Caveats: Single-article company universe but no representative article content or provided. Contract-award framing comes only through membership rationale, not direct evidence. No materiality, scale, or timing detail is available. |
| 389 | TelePIX lowweak | Opp 1 Risk 1 | Thesis: Reviewed evidence membership rationale suggests TelePIX is a space AI solutions company partnering on a VLEO satellite mission with an optical payload, which could imply long-horizon product or mission traction, but the reviewed sources provide no retained article summaries or direct positive evidence within the 90-day recent evidence window to support a stronger opportunity case. Why now: Why now is weak because coverage data shows zero articles after recent evidence window and zero evidence after recent evidence window, so there is no current retained catalyst evidence in the last 90 days despite membership support referencing article Caveats: Support exists only in the membership rationale, which cites article: but no or article summary is provided in the reviewed sources, so it cannot be cited as a factual claim under the the evidence standard. Evidence recent evidence review shows kept_rows 0 and coverage data shows evidence after recent evidence window 0. |
| 390 | Telesat Corp lowweak | Opp 1 Risk 1 | Thesis: No retained within the recent evidence window direct positive evidence is available in the reviewed sources, so there is not enough support for an opportunity thesis despite cohort relevance. Why now: Coverage data reports zero article IDs after recent evidence window and zero evidence after recent evidence window, preventing a recency-based ranking call. Caveats: Membership rationale references satellite communications and Lightspeed progress, but no article or retained evidence are supplied for ranking use. Public company status does not itself create a thesis without evidence. |
| 391 | Terran Orbital lowweak | Opp 1 Risk 2 | Thesis: The only reviewed sources support is a membership rationale stating Lockheed's modular satellite platform leverages Terran Orbital production, which suggests manufacturing relevance, but there is no in-window company evidence to support a stronger opportunity call. Why now: There is no valid near-term or long-horizon catalyst from the reviewed sources because coverage data shows zero evidence after recent evidence window; current state cannot be confirmed from local evidence. Caveats: No evidence remained after the 90-day recent evidence window. The reviewed sources includes only sparse membership rationale, not current direct evidence. |
| 392 | TESAT lowweak | Opp 1 Risk 1 | Thesis: TESAT appears in the reviewed sources only as a partner in Kepler Communications' ESA optical communications contract. Because relations are context-only in these reviewed sources, that cannot be used as direct counterparty propagation evidence, leaving no direct positive thesis support for TESAT itself (: not provided in reviewed sources). Why now: No inside-recent evidence window direct evidence are available, so there is no supported timing argument. Caveats: Relation evidence is context-only and cannot be propagated as direct contract evidence. No or representative article summary is provided. No company-specific materiality data is available. |
| 393 | TESAT Spacecom lowweak | Opp 1 Risk 1 | Thesis: TESAT Spacecom is only referenced in prior HydRON contract context involving other companies, which is too indirect to support a positive thesis under the the evidence standard. Why now: There is no within the recent evidence window direct company evidence. Membership rationale references, but no is provided and the support level is only provisional single-article context. Caveats: Support is explicitly supporting article context, not direct company-specific event evidence. No retained evidence after recent evidence window. Relations/context-only mentions cannot be used as counterparty propagation evidence. |
| 394 | Thales lowweak | Opp 1 Risk 1 | Thesis: A weak opportunity case exists only from the phase2 rationale, which says Thales Alenia Space was linked as prime contractor for Sentinel-1 Next Generation satellites, suggesting satellite manufacturing/radar exposure. However, the reviewed sources provide no available article summaries or evidence inside recent evidence window for Thales itself, and the rationale itself questions whether subsidiary evidence should propagate to the parent. Why now: There is no citable in-recent evidence window article summary or evidence row for Thales in these reviewed sources, and coverage data shows zero article ids after recent evidence window and zero evidence after recent evidence window. Caveats: Phase2 rationale references article ids: and: but no or summaries for them are included here. Parent/subsidiary propagation is explicitly uncertain in the reviewed sources rationale. No direct evidence were available after recent evidence window. |
| 395 | Trishul Space lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources only says Trishul Space was placed in T-Hub's ORBIT spacetech accelerator context, which is not enough by itself to establish a durable positive 1 year+ thesis without direct company-specific progress evidence. Why now: There is no available within the recent evidence window evidence row after the March 29, 2026 cutoff; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for Trishul Space. Caveats: Phase-2 membership rationale references article: but the reviewed sources provide no for citation. Accelerator participation context is weaker than direct commercial, funding, or technical milestone evidence. |
| 396 | True Anomaly Centennial lowweak | Opp 1 Risk 1 | Thesis: Potential long-horizon opportunity cannot be established from available evidence. The reviewed sources membership rationale says the company was selected in the U.S. Space Force Andromeda contract for space surveillance, but no direct within the recent evidence window evidence or article details are available for scoring. Why now: Why-now visibility is weak because the reviewed sources show zero evidence kept after recent evidence window for this company, so any claimed contract relevance lacks scoreable supporting detail in the current batch. Caveats: Reviewed evidence cites: in membership rationale but does not provide article summary or available evidence, so it cannot be used as direct scoring evidence. Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. Absence of negative evidence is not positive evidence. |
| 397 | ULA lowweak | Opp 1 Risk 1 | Thesis: ULA is identified as a launch provider in membership context, but the reviewed sources retains no 90-day positive evidence to support an investable long-horizon opportunity view. Why now: Coverage data shows zero retained article IDs and evidence after the recent evidence filter, so there is no recent thesis-driving evidence in the reviewed sources. Caveats: Only membership-level context is present in the served reviewed sources. No direct event, fact, or article-context evidence remains within the recent evidence window. Direction cannot be inferred from category membership alone. |
| 398 | Uncovr lowweak | Opp 1 Risk 1 | Thesis: A funding-roundup mention suggests some financing activity, but the reviewed sources have no usable direct positive evidence after recent evidence window and does not connect the company to a space-specific thesis. Why now: The only described context is a funding-roundup article referenced in phase2 rationale, but no post-recent evidence window evidence or are provided for thesis use. Caveats: Phase2 rationale says Uncovr was listed as having raised $7M in article: but no was provided in the reviewed sources. Despite support_counts mentioning dated event/facts, the company-level available evidence arrays are empty and coverage data shows evidence after recent evidence window = 0. Broad funding roundup context is weaker than direct company-specific event evidence. |
| 399 | United Launch Alliance lowweak | Opp 1 Risk 1 | Thesis: Insufficient admissible reviewed sources evidence to support a positive thesis within the 90-day recent evidence window, despite membership rationale identifying ULA as a rocket company tied to Vulcan and Atlas V contexts. Why now: Why now is unsupported because the reviewed sources contain no surviving article or evidence after the selected recent evidence window; business-state or catalyst timing cannot be judged from the provided materials. Caveats: Zero evidence survived after recent evidence filtering. Company membership in the cohort is not thesis attractiveness. No dated catalyst, performance update, or direct risk item is included. |
| 400 | Univity lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources indicates Univity is a satellite startup that raised capital and plans a large VLEO constellation, but no dated within the recent evidence window evidence or article summaries are available here to support a stronger positive thesis. Why now: No usable within the recent evidence window evidence were available after filtering; recency-based thesis formation is therefore not supported in these reviewed sources. Caveats: Coverage after recent evidence window is effectively empty in these reviewed sources. Membership rationale is not directional proof. |
Risk view
Showing rows 61-80 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 61 | Xoople mediummedium | Opp 6 Risk 4 | Thesis: Article-level context also highlights structural Earth observation monetization difficulty and long procurement cycles, creating real commercialization risk even after the raise. Why now: Xoople closed a $130 million Series B on April 6, 2026/07 and articles say the capital is for building out its constellation; for a 1 year+ horizon, that financing can enable product and deployment progress, but the same dated coverage warns the market has historically been hard to monetize. Evidence
Caveats: Positive support is mostly supporting article context rather than positive evidence. Commercialization warning is article context, not a company-specific deterioration event. No direct customer, backlog, or launch milestone evidence is available. |
| 62 | AAC Clyde Space AB lowweak | Opp 3 Risk 3 | Thesis: There is no direct adverse evidence in the reviewed sources, so risk is moderate-low and mostly reflects inability to verify current contract progression, funding conversion, or execution status from available evidence (: unavailable in reviewed sources). Why now: Why now is weak because the reviewed sources' recent evidence review and coverage data show zero available evidence after recent evidence window despite the membership rationale referencing a material contract. Caveats: No current evidence is provided for Contract claim appears only in membership rationale, not in available direct evidence fields. No recency-confirmed follow-through evidence is available. |
| 63 | Aavuus mediummedium | Opp 5 Risk 3 | Thesis: Aavuus remains early-stage, and the evidence is supporting article context rather than direct positive events; the same article describes only pre-seed funding, which implies execution and scaling risk over a 1 year+ horizon. Why now: The opportunity is timely because the retained article is dated June 9, 2026 and describes a current financing and product build phase rather than stale background context. That said, recency comes from source date/article date, and evidence grounding is still article-level rather than direct fact/events., June 9, 2026 Evidence
Caveats: Evidence is weak context and supporting article context, not direct structured positive event evidence. No explicit customer, contract, revenue, or regulatory milestone is cited. Same article appears in multiple rows and is not independent confirmation. |
| 64 | Applied Atomics lowweak | Opp 2 Risk 3 | Thesis: Risk is modestly elevated because the reviewed sources' membership rationale describes it as a startup that emerged from stealth and raised only a $4M pre-seed, implying early-stage execution and financing risk, but this is not backed by available dated evidence in the ranking payload. Why now: There is no available dated evidence in the reviewed sources after recent evidence filtering, so recency-based ranking support is weak. Caveats: No representative articles or evidence are available after recent evidence filtering for ranking support. The phase2 membership rationale mentions a $4M pre-seed and Star Reacher Network, but the cited supporting articles are not provided with usable article summaries or evidence in these reviewed sources. |
| 65 | Astrolab lowweak | Opp 3 Risk 3 | Thesis: No direct negative evidence is available; the main risk in this ranking is evidence insufficiency rather than a documented adverse development. Why now: Why-now support is weak because coverage data shows no evidence after recent evidence window, so the cited lunar contract context cannot be refreshed from available evidence. Caveats: Phase2 rationale cites, and: but no representative article or evidence are available for direct citation. Coverage data reports articles after recent evidence window = 0 and evidence after recent evidence window = 0. Private-company watch item rather than high-conviction ranked candidate. |
| 66 | Astroscale lowweak | Opp 5 Risk 3 | Thesis: No direct negative evidence is available. Remaining risk comes from the lack of post-recent evidence window evidence proving contract conversion, revenue realization, or mission execution scale. Why now: Why now is relatively constructive because a named partnership for on-orbit services can matter over a long strategic horizon, but exact timing and materiality cannot be validated from the reviewed sources because only membership rationale is visible. Caveats: Membership rationale references article ID: but the reviewed sources provide no or article summary. Relation counts are present in support metadata, but relations are context-only unless separately policy-gated. No direct positive or negative evidence arrays are populated. |
| 67 | Axelspace Corporation lowweak | Opp 3 Risk 3 | Thesis: No material negative evidence is present; risk is mainly execution and evidence-gap risk because current launch timing, deployment success, and monetization are not substantiated by the available reviewed sources evidence (: unavailable in reviewed sources). Why now: Why now is weak because the reviewed sources references a potentially important constellation expansion but provides no post-recent evidence window available evidence to confirm status or timing. Caveats: No current evidence is provided for No direct evidence remained after the recent evidence filter. Recency of constellation expansion cannot be validated from reviewed sources fields. |
| 68 | CAS Space lowweak | Opp 2 Risk 3 | Thesis: Risk is modestly elevated because the membership rationale describes IPO and reusable rocket development ambitions, both of which imply capital intensity and execution risk, but there is no available adverse evidence. Why now: There is no usable dated evidence available after recent evidence filtering, so the reviewed sources does not provide a clear timing catalyst. Caveats: The membership rationale references an IPO and Lijian-1 launch activity, but those source articles are not included with ranking-usable details in these reviewed sources. |
| 69 | CesiumAstro lowweak | Opp 5 Risk 3 | Thesis: The positive financing evidence is stale relative to the reviewed sources' 90-day recent evidence window. The article is dated February 14, 2026, which the reviewed sources say was dropped by the recent evidence filter, so there is no current-window evidence confirming whether financing momentum, backlog conversion, or product adoption continued Why now: There is no fresh catalyst inside the 90-day evidence window. The visible article was published on February 14, 2026 and is outside the cutoff date of March 29, 2026, so it is useful as background but weak for recency-sensitive ranking Evidence
Caveats: The visible positive article is outside the 90-day recent evidence window cutoff and was dropped from reviewed evidence. External supporting source context is allowed as evidence context but is not merged into primary data source. |
| 70 | ClearSpace mediummedium | Opp 7 Risk 3 | Thesis: Risks center on execution and evidence quality rather than explicit adverse news. The financing article carries internal chronology ambiguity because the page was published in 2026 but references a January 19, 2023 financing round, and the overall reviewed sources lack direct negative events, contract-performance data, or milestone completion proof. Why now: Why now is supported by recent dated context: on June 24, 2026, SpaceNews reported ClearSpace signed an MOU with Shield Space to develop sovereign space defense capabilities for the UK and allies, indicating adjacent market expansion. On May 19, 2026, the company site said it had finalized a EUR 26.7 million Series A and was ramping operations ahead of ClearSpace-1 scheduled to launch in 2026. These dated items fit a 1 year+ horizon because they point to ongoing commercialization and mission preparation. Evidence
Caveats: Most evidence is supporting article context, not direct positive events. The financing article published on May 19, 2026 references January 19, 2023 for the Series A round, so funding recency versus page recency should not be conflated. |
| 71 | D-Orbit lowweak | Opp 4 Risk 3 | Thesis: No direct negative evidence is present. Risk remains moderate because the evidence base is only one cited article with no available direct events, leaving uncertainty on commercialization, timeline, and conversion from demonstration activity to durable revenue. Why now: Why now is the partnership/demo claim referenced in article ID, but the reviewed sources includes neither nor explicit article timing beyond the article ID prefix, limiting recency precision. Caveats: Opportunity rests on membership rationale rather than fully available direct evidence. Referenced article ID has no in the reviewed sources. Demo activity is not the same as proven commercial traction. |
| 72 | Dawn Aerospace mediummedium | Opp 7 Risk 3 | Thesis: Risk is non-trivial because the thesis depends on execution of a global rollout in a capital-intensive reusable space transportation market, but the reviewed sources does not show direct adverse events. Risk is therefore moderate rather than high. Why now: The key catalyst is recent and explicit: on June 16, 2026 the company announced the Series B close and said the proceeds will finance global rollout and scaling of commercial and operational teams in the US and Europe. Evidence
Caveats: Evidence comes from a company-published article, so it is not fully independent. No direct structured positive event row is provided beyond supporting article context. |
| 73 | Earth Eye Co lowweak | Opp 2 Risk 3 | Thesis: Because the reviewed sources frames the company around surveillance/spy satellite activity rather than commercial traction, and provides no direct positive operating evidence, the name screens as a limited-visibility watchlist with modest evidence-based risk. Why now: Why now is weak because there are no available post-recent evidence window evidence, no article summaries, and no clear near- or long-horizon catalyst beyond generic association with a surveillance satellite. Caveats: Membership rationale cites article IDs and, but the reviewed sources provide no. Company is private and evidence coverage inside the recent evidence window is empty. |
| 74 | EDGX lowweak | Opp 4 Risk 3 | Thesis: Execution and financing risk remain material because the reviewed sources contain no kept direct evidence on follow-on funding, customer adoption, revenue conversion, or post-demo performance; technology demonstration does not by itself prove scale-up. Why now: The membership support references articles, and, implying a narrative of funding plus orbital demonstration, but active evidence remains empty after recent evidence filtering, limiting recency confidence. Caveats: In-orbit demo claim appears only in reviewed sources rationale, not available direct evidence. No evidence confirms whether the prior seed round falls within the current decision horizon relevance. No direct adverse evidence is present, but that is not proof of low fundamental risk. |
| 75 | Ellipsis Drive lowweak | Opp 4 Risk 3 | Thesis: Risk is mostly commercialization uncertainty. The reviewed sources does not provide direct negative evidence, but it also lacks direct available proof of revenue, customer conversion, or broader market adoption. Why now: Why now is the reviewed sources' claim that the company addresses a key EO data-processing bottleneck and has space-agency support, referenced to article ID: though no or timestamp detail was provided. Caveats: Claims come from membership rationale rather than direct evidence. Referenced article ID: lacks a reviewed sources. Support from agencies and target users is weaker than demonstrated contracted revenue. |
| 76 | EON Space Labs lowweak | Opp 1 Risk 3 | Thesis: The reviewed sources' clearest adverse context is that EON Space Labs was identified as one of the Indian private space companies affected by a PSLV failure, which could create execution, schedule, or financing ripple effects over a 1 year+ horizon, though the underlying article detail is not surfaced in the scoring evidence fields. Why now: Why now is stronger than for most names here because the phase2 rationale specifically ties EON Space Labs to a PSLV failure context via article: implying a concrete event rather than generic company context. However, conviction remains low because the reviewed sources omits the underlying event summary and dates in the evidence exposed here. Caveats: The adverse signal appears only in phase2 rationale, not in direct negative evidence. No article summary, quote, or timing detail is provided in the scoring fields. Impact magnitude on EON specifically cannot be quantified from these reviewed sources alone. |
| 77 | Eycore mediumweak | Opp 5 Risk 3 | Thesis: Risk remains moderate because the reviewed sources offers only one supporting article context and no direct positive event row beyond that summary, leaving unclear whether the satellite is generating revenue, delivering performance, or leading to follow-on orders. Why now: Why now is the dated first-satellite launch article from May 5, 2026, which is recent within the 90-day recent evidence window and relevant to a long-horizon de-risking story, though still early-stage. Evidence
Caveats: Evidence is supporting article context only, not a stronger structured positive event row. Single-article universe limits corroboration. No financing, customer, revenue, or performance follow-through evidence is provided. |
| 78 | GITAI mediummedium | Opp 6 Risk 3 | Thesis: Execution and commercialization risk remain meaningful because the retained evidence is still mainly company-provided article context and a technology demonstration milestone, not third-party validated contract wins, revenue conversion, or mission success; an undated directory listing that GITAI is 'operating' is weaker context and not recency proof. Why now: The key catalyst is recent and inside recent evidence window: on June 16, 2026, GITAI announced completion of the S3 flight model for an on-orbit servicing demonstration mission, which is directly relevant to a 1 year+ horizon because it may precede launch, demonstration, and downstream defense/commercial adoption over the next year. Evidence
Caveats: Primary evidence is from the company itself. No retained independent customer, contract, or revenue evidence is provided. The spaceindex.io entry is undated and should not be treated as recency proof. |
| 79 | Goonhilly Earth Station Ltd lowweak | Opp 3 Risk 3 | Thesis: The same reviewed sources rationale says Goonhilly is being acquired by Intuitive Machines, which can create integration, ownership, and business-state uncertainty over a 1 year+ horizon. Because no retained dated evidence are available, this risk is only moderately ranked. Why now: The only 'why now' available is the reviewed sources' statement that Goonhilly is being acquired by Intuitive Machines, cited in phase-2 support, and: but no, timestamps, or retained evidence are provided, so recency and sequence cannot be validated. Caveats: The reviewed sources rationale states Goonhilly has ground-station/COMSAT revenue and is being acquired by Intuitive Machines, tied to, and: but no or retained evidence are present. Coverage debug still shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Because chronology cannot be verified, transaction-state claims should be treated cautiously. |
| 80 | ICEYE highstrong | Opp 9 Risk 3 | Thesis: The reviewed sources does not show material adverse company-specific events; main risk is that most support is financing/context evidence rather than audited operating metrics or margins. Why now: On June 9, 2026 ICEYE disclosed a €450 million primary Series F at valuation above €10 billion, with total round size above €1 billion including secondary, and later June context also referenced a €300 million revolving credit facility and additional sovereign satellite demand; those are recent business-state signals for a 1 year+ horizon. Evidence
Caveats: Some support is supporting article context rather than company-specific positive evidence. Several supporting demand/customer references are undated, so recency is uncertain for those claims. |